细胞周期蛋白依赖激酶4/6抑制剂在膀胱癌治疗中的应用潜能

佟智超; 刘忠清; 曲天瑞; 徐万海

doi:10.13201/j.issn.1001-1420.2020.12.017

细胞周期蛋白依赖激酶4/6抑制剂在膀胱癌治疗中的应用潜能

- 哈尔滨医科大学附属第四医院泌尿外科(哈尔滨, 150001)
基金项目:
国家自然科学基金青年科学基金项目(No:82002688)

哈尔滨医科大学附属第四医院优秀青年项目(No:HYDSYYXQN202004)

详细信息

通讯作者: 徐万海,E-mail:xuwanhai@hrbmu.edu.cn

中图分类号: R737.14

收稿日期: 2020-01-10

Potential of cell cycle-dependent kinase 4/6 inhibitors in the treatment of bladder cancer

- Department of Urology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China

More Information

Corresponding author: XU Wanhai, E-mail: xuwanhai@hrbmu.edu.cn

Received Date: 10 January 2020

摘要

摘要: 细胞周期进展异常是膀胱癌的重要特征之一。高选择性的细胞周期蛋白依赖激酶(CDK)4/6抑制剂在膀胱癌中有潜在的应用前景,因为89%的膀胱癌患者存在细胞周期进程中关键基因的突变,预临床数据证实了它们作为单一或联合治疗策略的有效性。在这篇文章中,我们讨论了在膀胱癌中靶向CDK4/6的生物学原理,回顾了现有的临床证据,并进一步讨论了优化其临床应用所面临的挑战。
- 细胞周期 /
- 细胞周期蛋白依赖激酶4/6抑制剂 /
- 膀胱癌
Abstract: Dysregulated cell cycle progression is one of the key hallmarks of bladder cancer. Selective CDK4/6 inhibitors are promising antitumor agents, for 89% MIBC patients exert mutations among key mediators in cell cycle progression. Pre-clinical data demonstrated their potency as monotherapy or combination therapy strategy. In this article, we discuss the biological rationale for targeting CDK4/6 in bladder cancer, review the available clinical evidence, and further discuss the challenges of optimizing their use.
- cell cycle /
- CDK4/6 inhibitors /
- bladder cancer

HTML全文

参考文献(33)

[1]	O'Leary B,Finn RS,Turner NC.Treating cancer with selective CDK4/6 inhibitors[J].Nat Rev Clin Oncol,2016,13(7):417-430.
[2]	Peyressatre M,Prevel C,Pellerano M,et al.Targeting cyclin-dependent kinases in human cancers:from small molecules to Peptide inhibitors[J].Cancers(Basel),2015,7(1):179-237.
[3]	Pan Q,Sathe A,Black PC,et al.CDK4/6 inhibitors in cancer therapy:a novel treatement strategy for bdder cancer[J].Bladder Cancer,2017,3(2):79-88.
[4]	Petrelli F,Ghidini A,Pedersini R,et al.Comparative efficacy of palbociclib,ribociclib and abemaciclib for ER+ metastatic breast cancer:an adjusted indirect analysis of randomized controlled trials[J].Breast Cancer Res Treat,2019,174(3):597-604.
[5]	Robertson AG,Kim J,Al-Ahmadie H,et al.Comprehensive molecular characterization of muscle-invasive Bladder Cancer[J].Cell,2017,171(3):540-556 e525.
[6]	Malumbres M,Barbacid M.Cell cycle,CDKs and cancer:a changing paradigm[J].Nat Rev Cancer,2009,9(3):153-166.
[7]	Baldin V,Lukas J,Marcote MJ,et al.Cyclin D1 is a nuclear protein required for cell cycle progression in G1[J].Genes Dev,1993,7(5):812-821.
[8]	Hiebert SW,Chellappan SP,Horowitz JM,et al.The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F[J].Genes Dev,1992,6(2):177-185.
[9]	Harbour JW,Luo RX,Dei Santi A,et al.Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1[J].Cell,1999,98(6):859-869.
[10]	Sherr CJ,Roberts JM.CDK inhibitors:positive and negative regulators of G1-phase progression[J].Genes Dev,1999,13(12):1501-1512.
[11]	Paternot S,Bockstaele L,Bisteau X,et al.Rb inactivation in cell cycle and cancer:the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase[J].Cell Cycle,2010,9(4):689-699.
[12]	Klein ME,Kovatcheva M,Davis LE,et al.CDK4/6 Inhibitors:the mechanism of action may not be as simple as once thought[J].Cancer Cell,2018,34(1):9-20.
[13]	Zhang HS,Postigo AA,Dean DC.Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a,TGFbeta,and contact inhibition[J].Cell,1999,97(1):53-61.
[14]	Iwata H.Clinical development of CDK4/6 inhibitor for breast cancer[J].Breast Cancer,2018,25(4):402-406.
[15]	Rubio C,Martinez-Fernandez M,Segovia C,et al.CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 Status[J].Clin Cancer Res,2019,25(1):390-402.
[16]	Rentsch CA,Muller DC,Ruiz C,et al.Comprehensive molecular characterization of urothelial bladder carcinoma:a step closer to clinical translation[J]?Eur Urol,2017,72(6):960-961.
[17]	Sathe A,Koshy N,Schmid SC,et al.CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1[J].J Urol,2016,195(3):771-779.
[18]	Rose TL,Chism DD,Alva AS,et al.Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy[J].Br J Cancer,2018,119(7):801-807.
[19]	Goel S,DeCristo MJ,McAllister SS,et al.CDK4/6 Inhibition in Cancer:Beyond Cell Cycle Arrest[J]Trends Cell Biol,2018,28(11):911-925.
[20]	Tong Z,Sathe A,Ebner B,et al.Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer[J]J Exp Clin Cancer Res,2019,38(1):322.
[21]	Brandao M,Caparica R,Eiger D,et al.Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors[J].Ann Oncol,2019,30(Supplement_10):x27-x42.
[22]	Bonelli MA,Digiacomo G,Fumarola C,et al.Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells[J].Neoplasia,2017,19(8):637-648.
[23]	Herrera-Abreu MT,Palafox M,Asghar U,et al.Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer[J].Cancer Res,2016,76(8):2301-2313.
[24]	Jansen VM,Bhola NE,Bauer JA,et al.Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer[J].Cancer Res,2017,77(9):2488-2499.
[25]	Konecny GE.Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer[J].EBioMedicine,2019,43:9-10.
[26]	Kovatcheva M,Liao W,Klein ME,et al.ATRX is a regulator of therapy induced senescence in human cells[J].Nat Commun,2017,8(1):386.
[27]	Anders L,Ke N,Hydbring P,et al.A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells[J].Cancer Cell,2011,20(5):620-634.
[28]	Yoshida A,Lee EK,Diehl JA.Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6[J].Cancer Res,2016,76(10):2990-3002.
[29]	Lopez-Mejia IC,Lagarrigue S,Giralt A,et al.CDK4 Phosphorylates AMPKalpha2 to Inhibit Its Activity and Repress Fatty Acid Oxidation[J].Mol Cell,2017,68(2):336-349 e336.
[30]	Lee Y,Dominy JE,Choi YJ,et al.Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression[J].Nature,2014,510(7506):547-551.
[31]	Franco J,Balaji U,Freinkman E,et al.Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities[J].Cell Rep,2016,14(5):979-990.
[32]	Goel S,DeCristo MJ,Watt AC,et al.CDK4/6 inhibition triggers anti-tumour immunity[J].Nature,2017,548(7668):471-475.
[33]	Deng J,Wang ES,Jenkins RW,et al.CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation[J].Cancer Discov,2018,8(2):216-233.